Context: While respiratory infections are a leading cause of morbidity, there is little information on the costs of medically treating these conditions, or on their workplace impact. Objective: The purpose of this study was to estimate the economic burden of respiratory infections from the perspective of an employer. Design, setting, and participants: A total of 63,890 patients with at least one diagnosis for a respiratory infection in 1997 were identified in a claims database of a national Fortune 100 company. Outcome measures were compared to those of a 10% random sample of beneficiaries in the overall beneficiary population. Main outcome measures: The annual per capita costs for each category of respiratory infections were determined for beneficiaries of this major employer by analyzing all medical, prescription drug, and disability claims in 1997. Results: In 1997, the total cost to the employer per patient, as well as medical-service utilization, were higher among patients with respiratory infections than among beneficiaries in the overall beneficiary population. Significant variations exist in costs across the 11 selected respiratory infections. For example, annual per capita employer expenditures for patients with respiratory infections totaled $4,397, while expenditures for patients with pneumonia and patients with acute tonsillitis/pharyngitis were $11,544 and $2,180, respectively, as compared with costs for the average beneficiary, which was $2,368. Conclusions: Patients with respiratory infections present an important financial burden to employers. We estimate that the cost to employers of patients with respiratory infections in the United States in 1997 was $112 billion, including costs of medical treatment and time lost from work.
I
n 1996, 208 million episodes of respiratory disorders (including infectious and noninfectious respiratory conditions, such as asthma) were reported in the United States. 1 According to the Centers for Disease Control and Prevention, in 1996, the incidence per 100 persons for respiratory infections such as pneumonia, common cold, and influenza were 1.8, 23.6, and 36.0, respectively. 1 The incidence of respiratory infections is higher among the very young and the very old. 2 Given the high rate of respiratory conditions, understanding the medical-resource allocation and the economic burden incurred for these patients is important for payers demanding costeffective health care.
The focus of the research reported here is on the subset of respiratory infections, which are the leading cause of morbidity in developed countries. 3 Research on the epidemiology and treatment of various respiratory infections has provided important insights into prognostic factors for these conditions. 4 -6 However, there is little information on the economic costs of treating respiratory infections. Furthermore, very little research exists on the indirect costs of respiratory infections. While it was reported that morbidity due to respiratory infections led to 152 days lost from school per 100 youths, and 99 days lost from work per 100 employed persons in 1996, 1 no cost estimates were provided to quantify these economic losses.
Most studies on the economic cost of treating respiratory infections have focused on the direct health-care costs. Moreover, these studies rely on data from epidemiologic surveys, including diseasespecific questionnaires, and national health statistics, in addition to imputed cost estimates, to determine cost of illness, rather than using actual cost data. Rice 7 developed this widely used methodology to estimate the national cost of illness.
One study 8 of pneumonia found that the total direct cost, in 1995 dollars, of treating pneumonia patients Ͻ 65 years old in the United States was $3.6 billion per year. A similar study 9 was performed for acute exacerbations of chronic bronchitis, estimating the cost of both inpatient and outpatient services. Both studies relied on incidence data for patients with community-acquired respiratory infections from a variety of national survey databases, while costs were computed using the average Medicare cost per hospital day or physician visit and applying these costs to the number of hospital and outpatient visits for patients.
Other similar studies have been conducted for respiratory conditions. For example, a study 10 of chronic bronchitis and emphysema found that the total direct health-care costs for these illnesses were $11.7 billion, in 1996 dollars. This study, too, relied primarily on survey data from multiple national, state, and local sources, and costs for hospital and physician visits were derived from the Healthcare Cost and Utilization Project and national Medicare physician fee estimates in 1996. Another study 11 of this sort estimated the 1996 health-care costs for sinusitis to be $5.8 billion, of which $1.8 billion was for children Յ 12 years old.
Cost-of-illness studies such as those reported above are significantly limited by their reliance on self-reported data and assigned costs per day and per visit, as opposed to actual cost data. These studies are also confined to analysis of direct health-care costs. Our research provides a broader, more complete view of the economic burden associated with the treatment of respiratory infections, from the perspective of an employer. Using claims data from a national Fortune 100 company, we are able to compile the actual employer payments for the treatment of respiratory infections. Based on these data, we report a more accurate estimate of total costs by including not only direct costs (medical and prescription drugs), but also indirect costs (disability and sporadic absenteeism), which have not been previously quantified. In addition, findings are reported on the demographic characteristics of patients with respiratory infections and their treatment patterns.
Materials and Methods
The data come from a rich source of medical, prescription drug, and disability claims, which can be merged at the patient level, from distinct parts of one corporate benefits system. The data include all 1997 claims related to at least one of the 11 respiratory infection diagnoses (Table 1) for all beneficiaries (employees, spouses, dependents, and retirees) of a national Fortune 100 manufacturer. The company offers comprehensive health insurance and has a predominantly unionized workforce, 90% of whom are eligible for disability benefits. More than 100,000 beneficiaries, distributed across the country, were enrolled in one of the managed indemnity insurance plans of this company in 1997. Complete data are available for these individuals. Data for those enrolled in health maintenance organizations (who accounted for approximately 20% of enrollees) are not available, and these individuals are excluded from the sample. To ensure completeness of records, we have also excluded subjects Ͼ 65 years old in 1997, due to their enrollment in Medicare.
Medical claims include information on the date of service and nature of the ailment(s) as described by detailed diagnosis (International Classification of Diseases, ninth revision ) and procedure (current procedural terminology) codes. Similarly, prescription drug claims include national drug code information. Comparisons of treatment patterns, and health-care and workplace costs, are then made across employees with the conditions of interest. Since this study relies on insurance claims data, the findings are subject to the usual limitations of administrative data sets. Such limitations include possibly inaccurate diagnoses and incomplete assembly of claims (eg, missing bills, multiple plan coverage). 12 Direct and indirect costs are the actual cash payments by the employer, reported on an average, per-person basis annually. Our methods are similar to the approach taken by Burton and Conti 13 and Burton et al, 14 who used a "data warehouse" to analyze a range of other illnesses and document their effects on employee productivity. While data available here on the workforce burden of illness do not include measures of on-the-job productivity, they do include periods of disability and daily payments received by the employee. Data on shorter, medically related illness absences are not available, but are imputed in part, based on days when medical care was provided. If an employee was not receiving disability when medical care occurred during work days, these days are counted as sickness work-loss days in the case of hospital care, or as a half day in the case of office visits. Because the disability claims cover missed work days due to illness for periods of Ն 6 consecutive days for eligible workers, patients with disability claims also are assigned 5 sickness work-loss days. Work-loss costs refer here to employer payments for the sum of disability plus imputed medically related absence time. Barnett et al 15 provide a more complete description of these data.
Analyses were performed on the full respiratory infections sample, as well as separately on patients in each of the 11 respiratory infection diagnoses. 16 Claims data for patients with respiratory infections were contrasted with the overall beneficiary population, reflected in a 10% random sample of the employer's overall beneficiary population (ie, employees, spouses, and dependents), which included those with respiratory infections. Data are also provided on the subset of just employees with respiratory infections (n ϭ 19,156) and a 10% sample of employees.
Results
There were 63,890 beneficiaries with at least one claim for the treatment of at least 1 of the 11 defined respiratory infections in 1997 (Table 1) . There was considerable overlap among patients in each of the respiratory infection categories. For example, 51% of patients with a diagnosis of pneumonia also had a claim for symptoms of the respiratory system. The incidence for respiratory infections in the beneficiary population was 36%. This rate is consistent with the rate of acute respiratory conditions described for the overall US population. 1 In comparing the demographics of beneficiaries with respiratory infections to those of the overall beneficiary population, we find the gender distribution to be similar. However, consistent with the fact that the incidence of respiratory infections is higher among the very young and very old, the respiratory infections beneficiary sample contains a higher percentage of subjects Ͻ 6 years old than the overall beneficiary population (p Ͻ 0.0001; Table 2 ). Recall that subjects Ͼ 65 years old are not considered due to their Medicare enrollment. All results are reported on an annual basis for 1997. 
Treatment Patterns
Beneficiaries with respiratory infections had on average almost two times more medical claims (14.8 claims vs 7.6 claims, p Ͻ 0.0001) than did the average beneficiary in this population (Fig 1, left, A) . One reason for this is that beneficiaries with respiratory infections were identified based on the fact they submitted at least one claim for respiratory infections, unlike those in the overall beneficiary population, who may or may not have submitted a claim (Fig 1, middle, B) . The average number of claims for beneficiaries with respiratory infections was almost 1.5 times higher than for comparable users in the overall beneficiary population (14.8 claims vs 10.9 claims, p Ͻ 0.0001; Fig 1, right, C) . Surprisingly, while patients with respiratory conditions consumed large amounts of medical services, respiratoryspecific claims accounted for only a small share of the overall care received by patients with respiratory infections (3.0 of the 14.8 total claims were for respiratory-specific claims).
Because respiratory infections vary widely in their severity, medical-care utilization also varies considerably across the 11 categories of respiratory infection. This variation is best illustrated by comparing patients with pneumonia and patients with acute tonsillitis/pharyngitis (Fig 2) . Patients with pneumonia had the highest number of claims per person (27.0 claims), as well as the highest number of claims per user for inpatient services (21.9 claims), contrasted with patients with acute tonsillitis/pharyngi-
Cost Measures
Among patients treated for a respiratory infection in 1997, health-care and work-loss costs totaled $4,397 per beneficiary (and $6,838 per employee, in that subgroup of the population; Fig 3) . These per capita costs were approximately 1.8 times those of the overall beneficiary population and the subgroup of employees in the overall employer population ($2,368 and $3,815, respectively). Differences between the patients with respiratory infections and the overall beneficiary population, as well as between the subsets of employees in each of these groups, were statistically significant (p Ͻ 0.0001). The difference in costs between employers and beneficiaries with respiratory infections and the comparison groups was primarily related to an increase in the total number of claims. Only a small proportion of the increased number of claims were specific to respiratory infections. The difference between costs for beneficiaries and employees was in large part due to the higher costs for disability and absenteeism in the employees.
In general, there was considerable variation in costs by type of respiratory infection. For example, beneficiaries with pneumonia, symptoms of the respiratory system, and chronic bronchitis averaged the highest costs, at $11,544, $7,845, and $5,874 per employee, respectively (Table 3 ). Beneficiaries with acute tonsillitis/acute pharyngitis, strep throat, and acute upper respiratory tract infections of multiple or unspecified sites had the lowest costs, at $2,180, $2,642, and $2,791, respectively. The same analysis for only employees showed a similar pattern among respiratory infections. The distribution of costs varied by type of respiratory infection. Inpatient costs are the primary driver of the cost associated with patients with the most costly respiratory infections. For example, 63% of medical costs for patients with pneumonia and 47% of medical costs for patients with symptoms of the respiratory system were attributable to inpatient services ($6,316 and $3,098, respectively), compared with 28% and 25% for patients with acute upper respiratory tract infections and for patients with acute tonsillitis/pharyngitis ($613 and $448, respectively). Prescription drugs generally accounted for a small proportion of total costs among all types of respiratory infections (17%). While overall work absences accounted for approximately 35% of total costs for employees with respiratory infections, the cost varied as a percentage of total costs across type of respiratory infection. Analyzing the distribution of medical costs across the pneumonia patient population illustrates that expenses are concentrated among a relatively small group of patients who were disproportionately hospitalized. The most costly 10% of pneumonia patients (99% were hospitalized) accounted for 59% of the total cost of the entire pneumonia population. Meanwhile, the average hospitalization rate among patients with respiratory infections was significantly lower (15%). These findings are illustrated in Figure  4 , which shows that while the employer paid Ͼ $10,000 for approximately 25% of patients with pneumonia in 1997, similar expenditures were incurred for only 11% of patients with respiratory illness overall and an even smaller percentage (5%) of the overall beneficiary population.
Discussion
This work extends our previous research on the overall costs of pneumonia to employers. 16 The analysis here demonstrates the significant financial burden of respiratory infections to this employer and of variations in costs among different respiratory conditions.
Employer payments for employees with respiratory infections are almost twice those for beneficiaries in the overall beneficiary population, on average. Underlying these costs are the substantial utilization of services by patients with respiratory infections. Besides respiratory-specific claims, patients with respiratory infections submitted more claims for other types of medical services than those in the overall beneficiary population. Although medical-service utilization varied across the 11 categories of respiratory infections, in all cases respiratory infectionspecific claims (ie, claims associated with a diagnosis for respiratory infections) accounted for a small percentage of total medical-service utilization.
While this data set is for a single employer, it is possible to estimate the general magnitude of the *Includes care at patient's home, nursing/extended care facility, psychiatric day-care facility, substance abuse treatment facility, and independent clinical laboratories. †Aggregate employer costs is calculated by multiplying total costs by the No. of beneficiaries with a specific condition, as shown in Table 1 .
costs of patients with respiratory infections in the United States, from the perspective of an employer.
To the extent that the employed population in the nation is generally similar to the study population in the incidence of the respiratory infection, as well as health-care utilization and costs, the results of this study can be used to approximate the cost of patients with respiratory infections to the entire US employed population and their dependents. Our estimate is calculated by multiplying three numbers:
(1) an estimate of the employed population and their dependents in the United States, (2) the incidence of respiratory infections, and (3) the incremental cost of respiratory infections (ie, the difference between the average cost of the respiratory-infections sample and that of the overall beneficiary population). 17 ) Multiplying this population estimate by the incidence rate for the 11 respiratory conditions considered here (36%) and the incremental cost of respiratory infections ($2,029; Fig 3) , we estimate that the cost of patients with respiratory infections to employers in the United States in 1997 was $112 billion. This cost includes all of the health-care costs of treating patients with respiratory infections irrespective of the actual condition for which the patients were treated, as well as the work-loss costs to the employer. Hence, the costs include those of treating all of the comorbidities of respiratory infection claimants, as well as the costs of treatment explicitly for respiratory infections. However, dissecting the role of comorbidities in measuring the costs for treating respiratory infections (ie, whether respiratory infections exacerbate comorbid conditions, or comorbidities increase the susceptibility to or severity of respiratory infections) is a difficult issues and a topic for future research. While substantial, the estimated costs of respiratory infections presented here may underestimate the true burden of respiratory infections for a variety of reasons. For one, we excluded individuals Ͼ 65 years old in 1997, thereby removing from our patient sample a population with a high incidence rate of respiratory infection. Also, claims for otitis media were not included, as this is a disease primarily in the nonemployed (ie, Ͻ 6 years old) population. Additionally, sick time at home was not fully measured; we captured only that part of work loss due to illness that was associated with disability or medical treatment. Respiratory infections of dependents can also lead to workplace absences for caregivers who miss work to care for ill children and spouses. In addition, the actual payments for disability that are reported here reflect only a fraction of the total opportunity cost of the employer for workforce disruptions due to disability. Other likely workplace costs include reduced on-the-job productivity, administrative and training expenses for replacement workers, as well as days missed for sick time. Finally, there are also contagion effects from ill employees who continue to work and spread the respiratory infections among their coworkers, leading to additional work absence. Using an industry standard rule of thumb (eg, for every dollar of disability claims paid out, an employer incurs an additional $1.50 in workforce disruption) would imply that the disability costs reported here represent only 40% of the actual disability costs to the employer. Indeed, data in Watson Wyatt 18 suggest that a 1.5 multiple is a conservative estimate of the likely multiplier for employer disruption costs due to disability.
Alternatively, our analyses may have overestimated total costs of respiratory infections for two reasons. First, we included claims for "symptoms of the respiratory system" (ICD9 code 786.x). This is a condition (code) that captures a variety of several respiratory symptoms and signs, such as dyspnea, cough, abnormal sputum, chest pain, and abnormal chest sounds. Including these codes is reasonable because these symptoms and signs often represent acute respiratory infections and the coding reflects a nonspecific diagnosis. However, these symptoms and signs might also have represented noninfectious chest disorders. Thus, we may have included claims for comorbid conditions that do not directly relate to respiratory infections. As noted above, unraveling the issue of how comorbidities contribute to overall costs is complex. This analysis also highlights the variation in employer payments among types of respiratory infections. For example, although pneumonia is not common, it is an extremely expensive condition, and per-patient costs for patients with this condition are almost 50% greater than those with the next most costly condition considered here, symptoms of the respiratory system. Similarly, for certain conditions, especially pneumonia, the major cost item is inpatient services, yet a small proportion of patients drive most of the costs (Table 3, Fig 4) . For other conditions (eg, acute upper respiratory tract infections and tonsillitis/pharyngitis), inpatient costs are a much smaller proportion of total costs. Although these are more commonly reported conditions (Table 1) , they are still not as big an overall burden as pneumonia on the aggregate employer costs (Table 3 , overall costs). Such information may provide a basis for cost savings strategies (eg, pneumonia vaccines as a mandatory treatment).
These findings substantially increase our understanding of the costs and characteristics of patients with respiratory infections. Nevertheless, these findings are limited by the available data. First, because this study relies on insurance claims data, the findings are subject to the usual limitations of administrative data sets. Such limitations include possibly inaccurate diagnoses and incomplete assembly of claims (eg, missing bills, multiple plan coverage). 12 Second, many patients in the respiratory infections sample had a claim for more than one type of respiratory infection. Of the respiratory infections included in the analysis, patients with pneumonia were the most likely to have another respiratory infection, and they also had the highest employer payments. Seventy-seven percent of patients with pneumonia had at least one claim for another respiratory infection in 1997. In addition to comorbidity with other respiratory infections, it is also necessary to consider comorbidity with other nonrespiratory conditions. Many claims from patients with respiratory infections were not specific for the respiratory infections. For example, the risks from pneumonia and influenza may be greatest for patients with underlying comorbid conditions, such as heart disease, diabetes, and HIV infection. Unraveling the unique costs of respiratory infections relative to other comorbid conditions and the benefits of various prescription medications are topics for future research.
